Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in relapsed/refractory follicular lymphoma and other indolent B-cell lymphomas
NCT00875056Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2009
- Primary completion
- Sep 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
A Phase 2 trial of vorinostat in follicular lymphoma (FL), B-cell non-Hodgkin lymphoma (B-NHL), mantle cell lymphoma (MCL), sponsored by Merck & Co.. Started Apr 2009; status: completed.
02
Drugs
vorinostat
03
Conditions
follicular lymphoma (FL)B-cell non-Hodgkin lymphoma (B-NHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00875056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00875056.